Bruce Booth Sells 5,900 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Key Points

• Bruce Booth sold 5,900 shares of Kymera Therapeutics on April 22 at an average price of $89.96 for about $530,764, leaving him with 5,641 shares and representing a 51.12% reduction in his position; the transaction was executed under a pre-arranged Rule 10b5-1 plan.
• Booth has been an active seller recently, including a large disposition of 81,866 shares on March 2 for roughly $7.38 million, indicating sustained insider selling over the past months.
• Kymera shares traded at $84.91 (down $2.26) with a market cap of $6.93 billion, the company reported negative EPS and missed revenue estimates, yet analysts hold a consensus "Moderate Buy" rating with a $118.90 target.

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bruce Booth sold 5,900 shares of the firm's stock in a transaction on Wednesday, April 22nd. The shares were sold at an average price of $89.96, for a total value of $530,764.00. Following the completion of the sale, the director directly owned 5,641 shares in the company, valued at approximately $507,464.36. This represents a 51.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.08, for a total value of $9,008.00.
• On Wednesday, April 15th, Bruce Booth sold 3,135 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.10, for a total value of $282,463.50.
• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.95, for a total value of $197,890.00.
• On Tuesday, April 14th, Bruce Booth sold 4,159 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.97, for a total value of $374,185.23.
• On Monday, March 2nd, Bruce Booth sold 81,866 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.13, for a total value of $7,378,582.58.

Kymera Therapeutics Stock Performance

Shares of KYMR traded down $2.26 during trading hours on Friday, reaching $84.91. The stock had a trading volume of 393,678 shares, compared to its average volume of 710,755. Kymera Therapeutics, Inc. has a 12 month low of $28.06 and a 12 month high of $103.00. The stock has a market capitalization of $6.93 billion, a PE ratio of -23.07 and a beta of 2.28. The company's 50-day moving average is $84.58 and its two-hundred day moving average is $75.31.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing analysts' consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The firm had revenue of $2.87 million during the quarter, compared to the consensus estimate of $14.80 million. During the same quarter in the previous year, the company posted ($0.88) earnings per share. The firm's revenue was down 60.8% on a year-over-year basis. Equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC raised its position in shares of Kymera Therapeutics by 169.1% in the 4th quarter. SG Americas Securities LLC now owns 22,693 shares of the company's stock worth $1,766,000 after acquiring an additional 14,261 shares in the last quarter. Hudson Bay Capital Management LP raised its position in shares of Kymera Therapeutics by 362.7% in the 3rd quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company's stock worth $1,309,000 after acquiring an additional 18,134 shares in the last quarter. Federated Hermes Inc. bought a new position in shares of Kymera Therapeutics in the 3rd quarter worth about $31,622,000. Candriam S.C.A. raised its position in shares of Kymera Therapeutics by 24.4% in the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company's stock worth $10,847,000 after acquiring an additional 37,536 shares in the last quarter. Finally, Knights of Columbus Asset Advisors LLC bought a new position in shares of Kymera Therapeutics in the 3rd quarter worth about $1,069,000.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Barclays increased their price target on Kymera Therapeutics to $133.00 and gave the company an "overweight" rating in a research note on Tuesday, January 27th. Jefferies Financial Group began coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a "buy" rating and a $110.00 target price for the company. UBS Group raised their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the stock a "buy" rating in a research report on Tuesday, March 3rd. Citigroup lifted their price objective on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday, March 2nd. Finally, Wall Street Zen lowered Kymera Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $118.90.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.